Product logins

Find logins to all Clarivate products below.


Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Mature Markets

Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of wet age-related macular degeneration for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s wet age-related macular degeneration forecast will answer the following questions:

  • Of all people diagnosed with wet age-related macular degeneration, how many in each country in the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet age-related macular degeneration over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 6 wet age-related macular degeneration patient populations, as follows:

  • Total prevalent cases of wet AMD
  • Total prevalent cases of mixed AMD
  • Diagnosed prevalent cases of wet AMD
  • Undiagnosed prevalent cases of wet AMD
  • Diagnosed drug-treated cases of wet AMD
  • Diagnosed non-drug-treated cases of wet AMD

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…